Doctors are not safe with some patients.

Published Date: 16 Feb 2023

Many physicians have encountered one or more serious or potentially dangerous patients over the years, and according to Medscape research, patient trust has declined.

Read Full News

Latest News

US Judge Rejects Bayer Bid to Block Johnson & Johnson Prostate Cancer Drug Claims

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

This Test Could Predict Incontinence Risk After HoLEP

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

Smartphone App Helps Delay Ejaculation

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

US FDA Approves Lantheus' New Prostate Cancer Imaging Formulation

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Will a Smart Toilet Turn the Home Into a Diagnostic Center?

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Bayer Sues Johnson & Johnson Over Claim That Prostate Cancer Drug Cuts Risk Of Death

Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely advertising that its rival multibillion-dollar drug cuts the ⁠risk of death from prostate...

Todays Updates

WHO Warns Loosely Regulated Nicotine Pouches Risk Youth Addiction

The World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning ⁠that the highly addictive products were being...

Too Many Chest CTs for Incidental Lung Nodules?

Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

Todays Updates

WHO Warns Loosely Regulated Nicotine Pouches Risk Youth Addiction

The World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning ⁠that the highly addictive products were being...

Too Many Chest CTs for Incidental Lung Nodules?

Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

Latest News

A U.S. judge has rejected Bayer's request for an injunction to block Johnson & Johnson's alleged false advertising that ⁠its multibillion-dollar drug cuts the risk of...

Men with a shorter membranous urethra appear more likely to experience urinary incontinence after laser enucleation for benign prostatic hyperplasia, a new study shows.

The app improves sexual control and doubles ejaculation latency time in a randomized trial.

The U.S. Food and Drug Administration on Friday approved a new formulation of Lantheus Holdings' prostate ⁠cancer imaging agent, aimed at improving scanning access through...

Smart toilets show promise for passive monitoring of stool and urine to detect potential health issues, but challenges remain.

Bayer sued Johnson & Johnson on Monday, accusing the drugmaker of falsely advertising that its rival multibillion-dollar drug cuts the ⁠risk of death from prostate...

News All Time

Nivolumab Plus Chemotherapy in First Line Approved for Bladder Cancer.

Combination decreased death risk by 22%.

King Charles III's Operation; COVID-19 Timeline Under Question; FDA Approvals Reach Record High.

The staff of MedPage Today has compiled health news and commentary from around the web.

Noninvasive Treatment Effective in Bladder Cancer That Is Not Muscle-Invasive.

An investigational intrusive solution produced a 79% complete response rate.

For Prostate Cancer at Intermediate Risk, SBRT Is Not Less Effective Than Conventional RT.

Similar results are obtained from treatment lasting one to two weeks as compared to therapy lasting up to seven and a half weeks.

The new first-line standard for advanced bladder cancer was produced by a landmark trial.

When compared to chemotherapy, enfortumab vedotin-pembrolizumab doubles OS and PFS.

Should Patients With Advanced Prostate Cancer Get Off the Active Surveillance Train?

Clearly defined rules are needed.

Even in those with HIV, a single dose of antibiotics was able to cure early syphilis.

In a randomized trial, one dosage showed no worse results than a triple-dose regimen.

Removing Cancer Survivors From Oncologic Treatment.

A new approach to care is required.

Cabazitaxel Lower-Dose Schedule Is Viable for Elderly Patients With mCRPC.

Neutropenia of grade three or above, with a twelve-fold reduction in neutropenic consequences.

AR-Pathway Inhibitor Switch for mCRPC is Superseded by Radionuclide Therapy.

With 177Lu-PSMA-617, the time to radiographic progression was doubled.

An RCT Supports HIF-2a Inhibition in Advanced RCC.

Belzutifan outperforms everolimus in the event of immunotherapy-TKI failure.

Finding New Routes to Improve Renal Cell Carcinoma Outcomes.

It is necessary to intervene at several stages of the cancer immunity cycle in order to build on recent successes.

CAR T-Cell Therapy for Renal Cell Carcinoma: "We're Not There Yet".

Possibility of standard of care following current therapies, but significant barriers still need to be overcome.

In severe cases of renal cell carcinoma, tyrosine kinase inhibitor activity is present.

Reactions to the "special medication" zanzalintinib in patients exposed and not exposed to cabozantinib.

Dietary inflammation is associated with the development of urologic cancers.

In health research, the relationship between dietary habits and cancer risks is still a major focus. The has been the subject of a recent meta-analysis.

In infants, laparoscopic robotic pyeloplasty is safe and has a success rate comparable to open surgery.

The results of minimally invasive pyeloplasty (MIP) for the primary cause, ureteropelvic junction obstruction (UPJO), were examined in a recent study.

Recommended News For You

Dual-action mRNA vaccine takes aim at aggressive skin cancer

Drop in credit score after cancer diagnosis linked to increased mortality

10-year study shows tomosynthesis improves breast cancer detection

A global study demonstrates that screening for lung cancer significantly raises the long-term survival rate.

Underprescribed for Alcohol Use Disorder is pharmacotherapy.

In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.

findings from the measurement of disability weights in China with an emphasis on the impact of disease burden.

Recommended Articles For You

Unlocking the Potential of Lutathera: A Revolutionary Cancer Treatment 

The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies 

Mastering Prostate Cancer Care: CME, Certification, Digital Tools, and Evidence-Based Strategies 

Personalized Neoantigen Vaccines and the Promise of a Less Toxic Future in Pediatric Oncology 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.

2.

Photopenia on [18F]FDG PET/CT Predicts Benign Renal Lesions

3.

Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.

4.

When a Groundbreaking Cancer Therapy Causes Cancer.

5.

Study sheds light on challenges for women of color after breast cancer surgery

1.

Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies

2.

What You Need to Know About the Early Warning Signs of Colon Cancer 

3.

Revolutionizing Thyroid Cancer: Advances in Molecular Genetics and Personalized Treatment Approaches

4.

Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide

5.

Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

2.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III

3.

Efficient Management of First line ALK-rearranged NSCLC

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI

5.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot